Related by context. All words. (Click for frequent words.) 66 cell lymphoma CTCL 66 cutaneous T cell 64 lymphoma CTCL 63 medullary thyroid cancer 62 relapsed refractory multiple myeloma 62 NSCLC 61 relapsed refractory 61 cutaneous T 61 registrational trial 61 leukemia AML 60 IMGN# 60 CLL 60 Cutaneous T 60 hematologic malignancies 60 neuroendocrine tumors 60 heavily pretreated 60 romidepsin 60 bendamustine 59 lupus nephritis 59 HuMax CD4 59 axitinib 59 GIST 59 myelodysplastic syndrome MDS 59 indolent NHL 59 stage IIIB 59 hepatocellular carcinoma 59 Xanafide 58 Amigal 58 leukemia CLL 58 HBeAg negative 58 relapsing multiple sclerosis 58 hepatocellular carcinoma HCC 58 advanced hepatocellular carcinoma 58 forodesine 58 cell lymphomas 58 myelofibrosis 58 refractory Hodgkin lymphoma 58 B CLL 58 refractory CLL 58 recurrent NSCLC 58 recurrent glioblastoma 58 relapsed leukemia 58 chronic lymphocytic leukemia CLL 58 IBS C 58 TREANDA 58 soft tissue sarcomas 58 pediatric acute lymphoblastic 57 vismodegib 57 Chronic lymphocytic leukemia 57 relapsed SCLC 57 metastatic malignant melanoma 57 T Cell Lymphoma 57 HCV infection 57 multiple myeloma MM 57 refractory multiple myeloma 57 cell malignancies 57 JAK inhibitor 57 advanced NSCLC 57 AP# [003] 57 metastatic hormone refractory 57 renal cell carcinoma 57 Alemtuzumab 57 IV melanoma 57 recurrent GBM 57 hepatocellular cancer 57 refractory chronic lymphocytic 57 relapsed multiple myeloma 57 refractory acute myeloid 57 Hodgkin lymphoma HL 57 leukemia ALL 57 Sezary syndrome 57 unresectable 56 metastatic colorectal cancer 56 recurrent glioblastoma multiforme 56 malignant pleural mesothelioma 56 cell chronic lymphocytic 56 post herpetic neuralgia PHN 56 Myelofibrosis 56 Genasense ® 56 essential thrombocythemia 56 Amrubicin 56 Plicera 56 hepatitis C HCV 56 chronic hepatitis B 56 carcinoid syndrome 56 PNP inhibitor 56 mildly symptomatic 56 phase IIb clinical 56 HRPC 56 DLBCL 56 refractory AML 56 phase IIb trial 56 refractory PTCL 56 histologies 56 diabetic neuropathic pain 56 haematologic malignancies 56 deforolimus 56 antibody MAb 56 SJIA 56 cell acute lymphoblastic 56 unresectable stage 56 metastatic melanoma 56 chronic HBV infection 56 vandetanib 56 tanespimycin 56 HER2 positive metastatic breast 56 castration resistant prostate cancer 56 Virulizin ® 56 Li Fraumeni Syndrome 56 oral ridaforolimus 56 fibromyalgia syndrome 56 metastatic malignant 56 IIIB NSCLC 56 Romidepsin 56 registrational 56 sunitinib malate 56 Ceflatonin 56 chronic myeloid leukemia CML 56 acute myelogenous leukemia AML 55 non metastatic osteosarcoma 55 Aflibercept 55 Zolinza 55 cell lymphoma PTCL 55 riociguat 55 superficial bladder cancer 55 Phase Ib clinical 55 metastatic renal cell carcinoma 55 GvHD 55 OPAXIO 55 IV NSCLC 55 Myelodysplastic Syndrome 55 HQK 55 pheochromocytoma 55 ACZ# 55 hematological cancers 55 carcinoid tumors 55 Mantle Cell Lymphoma 55 Glioblastoma Multiforme 55 late onset Pompe 55 elacytarabine 55 Arranon 55 enzastaurin 55 Metastatic 55 Epratuzumab 55 Daclizumab 55 previously untreated follicular 55 dirucotide 55 metastatic bladder 55 Hepatocellular Carcinoma HCC 55 Follicular lymphoma 55 metastatic RCC 55 Pixantrone 55 NYHA Class II 55 lymphomas 55 Phase Ib 55 Renal cell carcinoma 55 anti angiogenic therapy 55 lorvotuzumab mertansine 55 refractory cutaneous T 55 Bronchiectasis 55 YONDELIS 55 Gleevec resistant 55 INCB# [002] 55 mycosis fungoides 55 Genz # 55 remission induction 55 acute myeloid 55 obatoclax 55 PROVENGE 55 Myelodysplastic Syndrome MDS 55 hematological malignancies 55 follicular lymphoma 55 Leukemias 55 macroglobulinemia 55 Gemzar ® 55 Campath alemtuzumab 55 Phase III clinical 55 Cimzia TM 55 octreotide 55 papillary renal cell carcinoma 55 histone deacetylase HDAC inhibitor 55 PANVAC VF 55 sorafenib Nexavar 55 Perifosine 55 placebo controlled clinical 55 ara C 55 Voreloxin 55 alvespimycin 55 systemic ALCL 55 invasive bladder 55 Tamibarotene 55 Myelodysplastic syndromes MDS 54 docetaxel Taxotere ® 54 ALCL 54 INCB# [001] 54 Dacogen injection 54 cardio renal 54 cell lymphoma ALCL 54 Ceflatonin R 54 AVONEX ® 54 SAR# [004] 54 histologically confirmed 54 Traficet EN 54 HER2 positive breast cancer 54 Evoltra ® 54 homozygous familial hypercholesterolemia 54 relapsing MS 54 AEG# 54 ISTODAX 54 LUMINATE 54 HuMax EGFr 54 multiple myeloma 54 daclizumab 54 solid tumors 54 CLL SLL 54 MGd 54 mRCC 54 HCV SPRINT 54 UPLYSO 54 GISTs 54 receptor tyrosine kinase inhibitor 54 Irinotecan 54 Clolar 54 severe oral mucositis 54 lymphoid malignancies 54 NeuroStar TMS Therapy 54 CYT# potent vascular disrupting 54 refractory CTCL 54 refractory metastatic 54 EOquin TM 54 brain metastases 54 orphan designation 54 AA amyloidosis 54 eltrombopag 54 satraplatin 54 IMC A# 54 Phase III clinical trials 54 acute leukemias 54 PXD# 54 TRISENOX 54 posaconazole 54 Cell Lymphoma 54 systemic lupus erythematosus 54 Phase #b/#a clinical 54 eosinophilic asthma 54 systemic anaplastic large 54 pediatric malignancies 54 SUTENT 54 elotuzumab 54 Torisel 54 ProMune 54 Renal Cell Carcinoma RCC 54 relapsing remitting multiple sclerosis 54 pralatrexate 54 acute coronary syndromes ACS 54 tumor lysis syndrome 54 ankylosing spondylitis AS 54 tivozanib 54 Glufosfamide 54 vinorelbine 54 relapsing remitting 54 hormone refractory metastatic prostate 54 EOquin 54 glufosfamide 54 ponatinib 54 ANTEGREN 54 Insegia 54 orphan medicinal product 54 metastatic disease 54 OncoVEX GM CSF 54 HCV infected 54 Omacetaxine 54 Xcytrin 54 generation purine nucleoside 54 Waldenstrom macroglobulinemia 54 postherpetic neuralgia 54 EGFR mutation positive 54 OMNARIS HFA 54 metastatic gastric 54 cirrhosis liver failure 54 ISTODAX ® 54 Severe Sepsis 54 HBeAg positive 54 hypereosinophilic syndrome 54 Icatibant 54 refractory indolent non 54 JAK2 inhibitor 54 chronic HCV 54 oral mucositis 54 aflibercept 54 radiation sensitizer 54 mCRC patients 54 Urocidin 54 recurrent ovarian cancer 53 systemic fungal infections 53 atypical Hemolytic Uremic Syndrome 53 SNT MC# 53 small lymphocytic lymphoma 53 erlotinib Tarceva ® 53 LEUKINE 53 Troxatyl 53 non resectable 53 myelodysplastic syndromes MDS 53 ADVEXIN 53 Lenalidomide 53 HER2 positive 53 Folotyn 53 Chronic Myeloid Leukemia CML 53 abiraterone acetate 53 INC# 53 complete remissions 53 diarrhea predominant irritable 53 refractory lymphoma 53 Phenoptin 53 randomized Phase 53 anticancer therapy 53 investigational compound 53 Arcalyst 53 neuroendocrine cancers 53 Non Hodgkin 53 IV metastatic melanoma 53 ocrelizumab 53 Golimumab 53 gastrointestinal stromal tumor GIST 53 chronic lymphocytic leukemia 53 gastric cancers 53 RRMS patients 53 IV malignant melanoma 53 TroVax 53 Chronic Lymphocytic Leukemia CLL 53 HoFH 53 gastrointestinal stromal tumors GIST 53 randomized Phase IIb 53 MELAS 53 ThermoDox ® 53 Evoltra TM 53 depsipeptide 53 metastatic GIST 53 veltuzumab 53 pancreatic adenocarcinoma 53 APPRAISE 53 diabetic nephropathy 53 Aplidin 53 non metastatic resectable 53 tamibarotene 53 CTEPH 53 chronic ITP patients 53 Relapsed Refractory 53 lumiliximab 53 chronic ITP 53 IL# PE#QQR 53 actinic keratosis 53 squamous cell carcinoma SCC 53 Blinatumomab 53 anti leukemic 53 Acute myeloid leukemia 53 sunitinib 53 Actemra 53 pancreatic NET 53 nodular BCC 53 cholangiocarcinoma 53 Nexavar ® 53 bosutinib 53 AEGR 53 Acute Myelogenous Leukemia AML 53 Phase 2b trial 53 Triapine 53 grade cervical intraepithelial 53 Gorlin syndrome 53 gemcitabine carboplatin 53 non Hodgkin lymphomas 53 satraplatin Phase 53 MPS VI 53 TELINTRA 53 DEB# 53 BRAF V# mutation 53 Brentuximab Vedotin SGN 53 Pralatrexate 53 virus HCV infection 53 gemcitabine Gemzar ® 53 hormone refractory prostate cancer 53 RRMS 53 imatinib resistant 53 Azedra 53 YONDELIS R 53 HCV genotype 1 53 post herpetic neuralgia 53 Metastatic Colorectal Cancer 53 JAK1 53 chronic HCV infection 53 velaglucerase alfa 53 Nimotuzumab 53 Onco TCS 53 Ixempra 53 Alzhemed TM 53 imatinib Gleevec ® 53 zanolimumab 53 nonalcoholic steatohepatitis NASH 53 tocilizumab 53 myelodysplastic syndromes 53 calcineurin inhibitors 53 advanced metastatic renal 53 Proxinium TM 53 metastatic pancreatic 53 sarcomas 53 phase Ib 53 metastatic 53 familial amyloidotic polyneuropathy FAP 53 myelofibrosis MF 53 Phase 2a trial 53 IMC #B 53 BRIM3 53 Chronic Lymphocytic Leukemia 53 completely resected 53 Non Hodgkin lymphoma 53 essential thrombocythemia ET 53 dasatinib Sprycel 53 regorafenib 53 Rituxan rituximab 53 Taxotere ® 53 relapsed mantle 53 mixed dyslipidemia 53 baminercept 53 trabectedin 53 cutaneous melanoma 53 BAY #-# 53 Telintra 53 metastatic renal cell 53 Chronic Myeloid Leukemia 53 RhuDex ® 53 EGFR inhibitors 53 Tarceva TM 53 Cholangiocarcinoma 53 dosing cohort 53 StemEx 53 pancreatic neuroendocrine tumors 53 CTAP# Capsules 53 biliary tract cancer 53 cell lung cancer 53 Cloretazine 53 cancer cachexia 53 fungoides 53 PEGylated interferon beta 1a 53 IIIA NSCLC 53 Phase #/#a trial 53 TACI Ig 53 arthritis PsA 53 hematological malignancy 53 idiopathic pulmonary fibrosis IPF 53 pediatric Crohn disease 53 OHR/AVR# 53 relapsed GBM 53 relapsed ovarian cancer 53 clofarabine 53 situ CIS 53 evaluating REVLIMID 53 perifosine 53 FOLOTYN 53 ALN TTR 53 follicular NHL 53 chlorambucil 53 HDAC Inhibitor 53 huN# DM1 53 pivotal Phase III 53 liver metastases 53 hypoparathyroidism 53 dasatinib 52 Diabetic Macular Edema 52 Ofatumumab 52 Acute Coronary Syndromes ACS 52 AVASTIN 52 Orphan Drug 52 Etanercept 52 myeloproliferative disorders 52 Marqibo 52 carfilzomib 52 Ulcerative Colitis 52 cell lymphoma 52 Hodgkin lymphoma NHL 52 multi kinase inhibitor 52 sorafenib 52 CHOP chemotherapy 52 treatment naive genotype 52 Acute Leukemia 52 ruboxistaurin 52 Allovectin 7 ® 52 Neuvenge 52 dasatinib Sprycel ® 52 TheraCIM 52 Cushing Syndrome 52 proliferative diabetic retinopathy 52 XmAb# 52 RG# [001] 52 HGS# 52 blinatumomab 52 ENDEAVOR IV 52 bone metastasis 52 MAGE A3 ASCI 52 myeloproliferative 52 allogeneic stem cell 52 T DM1 52 phase IIa clinical 52 relapsing remitting MS RRMS 52 Phase III randomized controlled 52 TMC# C# 52 androgen independent 52 Advanced Renal Cell 52 resectable 52 myeloproliferative neoplasms 52 standard chemotherapy regimen 52 XL# [003] 52 minimally symptomatic 52 Nexavar sorafenib 52 lymphoproliferative disorders 52 ErbB2 positive 52 Ozarelix 52 CIMZIA ™ 52 huC# DM4 52 myelofibrosis polycythemia vera 52 SCCHN 52 bone metastases 52 MDV# 52 Pemetrexed 52 apremilast 52 ozarelix 52 basal cell carcinoma BCC 52 sJIA 52 Metastatic breast cancer 52 Exelixis XL# 52 MabCampath 52 haematological cancers 52 relapsing remitting MS 52 Diffuse Large B 52 T#I [002] 52 ENESTnd 52 gastrointestinal stromal tumor 52 sodium glucose cotransporter 52 Fludarabine 52 vemurafenib 52 neoadjuvant treatment 52 LHRH agonists 52 SUTENT ® 52 briakinumab 52 Adenocarcinoma 52 advanced metastatic prostate 52 Vorinostat 52 valopicitabine 52 relapsed CLL 52 vidofludimus 52 Panzem R NCD 52 hematologic disorders 52 ZYBRESTAT 52 evaluating tivozanib 52 ASA# 52 Fabry Disease 52 tolevamer 52 opioid induced constipation 52 Chronic myeloid leukemia 52 TroVax ® 52 Acute Myeloid Leukaemia AML 52 BrachySil TM 52 ZACTIMA 52 XYOTAX TM 52 allogeneic bone marrow 52 pancreatic islet cell 52 carboplatin paclitaxel 52 TRO# 52 Acute lymphoblastic leukemia 52 lintuzumab 52 oral Hycamtin 52 Bronchitol 52 T#I mutation 52 IMA# 52 APTIVUS r 52 chronic idiopathic thrombocytopenic purpura 52 Bezielle 52 Onrigin 52 myeloproliferative diseases 52 alemtuzumab 52 mapatumumab 52 MEK inhibitors 52 RezularTM 52 Vandetanib 52 SHPT 52 opioid induced constipation OIC 52 Akt inhibitor 52 Vimpat ® 52 systemic lupus erythematosus SLE 52 OvaRex R 52 IRESSA 52 pseudobulbar affect PBA 52 novel histone deacetylase 52 Bortezomib 52 platinum refractory 52 gefitinib Iressa 52 Zarnestra 52 investigational immunotherapy 52 fluoropyrimidine 52 Clofarabine 52 adult chronic ITP 52 ACTEMRA TM 52 rituximab refractory 52 malignant pleural mesothelioma MPM 52 Uricase PEG 52 Velcade bortezomib 52 ofatumumab 52 refractory angina 52 Crohn disease 52 talactoferrin 52 symptomatic BPH 52 Acute Myeloid Leukemia 52 PAOD 52 farletuzumab 52 Myelodysplastic syndrome 52 dacetuzumab 52 apaziquone 52 Arzerra ofatumumab 52 Lymphocytic 52 AQ4N 52 ACTEMRA 52 HCV 52 Hsp# Inhibitor 52 Lung transplantation 52 anaplastic thyroid cancer 52 TORISEL 52 NOMID 52 multicentric 52 pan HDAC inhibitor 52 Delcath PHP System 52 ZOLINZA 51 NSABP 51 voreloxin 51 cell carcinoma 51 Sudhir Agrawal D.Phil 51 HyperAcute 51 gastrointestinal stromal tumors 51 linaclotide 51 imatinib mesylate Gleevec 51 acute GvHD 51 Rheumatoid Arthritis RA 51 sorafenib tablets 51 BEXXAR 51 tumors GIST 51 rheumatoid arthritis psoriatic arthritis 51 Fludara 51 Cloretazine R VNP#M 51 biologic therapy 51 Multiple Myeloma MM 51 atypical hemolytic uremic syndrome 51 gastric cancer 51 Laquinimod 51 non squamous 51 cytokine refractory 51 TELCYTA 51 Gefitinib 51 galiximab 51 Azixa 51 pegylated interferons 51 peritumoral brain edema 51 dose escalation Phase 51 haematological malignancies 51 cancer mCRC 51 Kit CD# positive 51 malignant neoplasms 51 BR.# 51 sunitinib Sutent 51 Severe Primary IGFD 51 Sebivo 51 pain palliation 51 ganetespib 51 Gaucher Disease 51 Safinamide 51 neovascular AMD 51 thalidomide Thalomid 51 ThermoDox R 51 DAVANAT 51 relapsed MM 51 pomalidomide 51 ELACYT 51 evaluable patients 51 alemtuzumab Campath 51 heterozygous FH 51 refractory 51 anti TNF 51 hematologic cancers 51 metastatic HRPC 51 EGFR expressing 51 amrubicin 51 vorinostat 51 AGILECT R 51 RhuDex R 51 refractory gout 51 Ilaris 51 CALGB 51 hormone refractory 51 glioblastoma multiforme GBM 51 Virulizin R 51 Fludara ® 51 ZEVALIN 51 refractory DLBCL 51 omacetaxine mepesuccinate 51 XYOTAX 51 carcinoid cancer 51 follicular non 51 Glioblastoma 51 rALLy clinical trial 51 oral prodrug 51 Soft Tissue Sarcoma 51 L BLP# 51 JAK inhibitors 51 commercialize deforolimus 51 castrate resistant prostate cancer 51 follicular lymphoma FL 51 Catena ® 51 carcinoma 51 refractory metastatic colorectal cancer 51 orally administered inhibitor 51 myelodysplasia 51 BCR ABL inhibitor 51 StemEx R 51 Raptiva ® 51 ixabepilone 51 acyclovir Lauriad R 51 Philadelphia Chromosome Positive 51 recurrent metastatic 51 soft tissue sarcoma 51 histone deacetylase inhibitor 51 chronic eosinophilic leukemia 51 HBeAg negative chronic hepatitis 51 SNT-MC#/idebenone 51 ONX 51 chronic hepatitis C. 51 mTOR inhibitor 51 CRVO 51 Acute Myeloid Leukemia AML 51 LUX Lung 51 KIACTA ™ 51 DOXIL 51 rindopepimut 51 nucleoside analogue 51 non alcoholic steatohepatitis 51 docetaxel Taxotere R 51 ADHF 51 refractory colorectal cancer 51 cervical carcinoma 51 recurrent glioma 51 EFAPROXYN 51 chronic angina 51 epithelial tumors 51 Afinitor 51 panitumumab Vectibix 51 Quinamed 51 invasive aspergillosis 51 candidemia 51 Inflammatory Bowel Disease 51 methylnaltrexone 51 BCG refractory 51 REMICADE ® 51 BRAF mutated 51 malignant lymphoma 51 null responder HCV 51 TYZEKA 51 VFEND 51 glioblastoma 51 FOLOTYN ® 51 metastatic renal 51 mertansine 51 fidaxomicin 51 OMAPRO 51 dirucotide MBP# 51 afatinib 51 placebo controlled Phase 51 PF # [001] 51 mCRC 51 terlipressin 51 FTY# 51 polycythemia vera essential thrombocythemia 51 GW# [003] 51 systemic juvenile idiopathic 51 humanized monoclonal antibody 51 romiplostim 51 LBH# 51 Phase 2b study 51 MALT lymphoma 51 RITUXAN 51 Simulect 51 stage IIIb IV 51 non squamous NSCLC 51 cangrelor 51 K ras mutations 51 Nuvion 51 temsirolimus 51 advanced medullary thyroid 51 Pirfenidone 51 cell carcinoma RCC 51 TG MV 51 COPREXA 51 Malignant Melanoma 51 MabThera Rituxan 51 chronic myeloid 51 diabetic macular edema 51 Ambrisentan 51 metastatic breast cancer 51 Congenital Emphysema 51 leukaemias 51 homozygous FH 51 relapsing forms 51 HYCAMTIN 51 MNTX 51 pulmonary hypertension PH 51 squamous non 51 CEQ# 51 differentiated thyroid 51 LHRH receptor positive 51 null responder 51 PsA 51 resistant ovarian cancer 51 Targretin 51 Junovan 51 HuMax CD# 51 fosbretabulin 51 prostate cancer CRPC 51 hypomethylating agents 51 lymphocytic leukemia 51 Satraplatin 51 targeting CD# 51 Pfizer Sutent 51 LHON 51 chimeric monoclonal antibody 51 BRAF inhibitor 51 Metastatic Melanoma 51 TYKERB 51 INCB# [003] 51 metastatic liver 51 HDACi 51 HBeAg positive patients 51 squamous histology 51 Follicular Lymphoma 51 Duchenne Muscular Dystrophy DMD 51 lasofoxifene 51 Sorafenib 51 interferon gamma 1b 51 doublet chemotherapy 51 Evoltra 50 oral deforolimus 50 esophageal candidiasis 50 NSCL cancer 50 xanthine oxidase inhibitor 50 efalizumab 50 metastatic colorectal 50 transitional cell carcinoma 50 abatacept 50 B Cell Lymphoma 50 RhuDex TM 50 rilonacept 50 Symadex 50 TNF blocker therapy 50 Phase 2b Clinical Trial 50 nonsmall cell lung cancer 50 sargramostim 50 Phase 1b clinical 50 EndoTAGTM 1 50 Phase 1b 50 Allovectin 7 50 gastric adenocarcinoma 50 mycophenolate mofetil 50 EGFR mutations 50 Mipomersen 50 anticancer compound 50 Cell Lung Cancer 50 Doxil ® 50 Apaziquone 50 treatment naïve genotype 50 squamous cell lung cancer 50 RTOG 50 LymphoStat B 50 IGF 1R inhibitor 50 Xcellerated T Cells 50 canakinumab 50 phase IIb 50 heavily pretreated patients 50 CoFactor 50 zalutumumab 50 antiangiogenic agent 50 Glioma 50 psoriasis 50 HER2 overexpression 50 AA Amyloidosis 50 phase IIb study 50 transthyretin amyloidosis 50 Toxicities 50 Enzastaurin 50 vascular disrupting agent 50 evaluable subjects 50 Idiopathic pulmonary fibrosis 50 pertuzumab 50 tyrosine kinase inhibitors 50 olaparib 50 noninfectious uveitis 50 micafungin 50 multicenter Phase III 50 disease modifying 50 pancreatic carcinoma 50 evaluating mipomersen 50 Vicinium TM 50 paragangliomas 50 cSSSI 50 Alpharadin 50 Asentar 50 Hemophilia B 50 histological subtype 50 subependymal giant cell 50 glioblastoma tumors 50 Glioblastoma multiforme GBM 50 malignant fibrous histiocytoma 50 cediranib 50 Leber Hereditary Optic Neuropathy 50 clinical trial 50 Cell Lymphoma CTCL 50 Langerhans cell histiocytosis 50 ulcerative colitis UC 50 ceftazidime 50 Erlotinib 50 Navelbine ® 50 carcinomas 50 cytotoxic chemotherapy 50 eribulin mesylate 50 Dalbavancin 50 Talabostat 50 ToGA 50 fallopian tube cancers 50 Systemic Lupus Erythematosus SLE 50 pemphigus vulgaris 50 dacarbazine DTIC 50 NUVIGIL 50 refractory acute promyelocytic 50 palifermin 50 myeloid 50 alefacept 50 PARP inhibitor 50 unresectable liver cancer 50 Myelodysplastic syndromes 50 colorectal liver metastases 50 NCCTG 50 decitabine 50 PNH patients 50 trans retinoic acid 50 refractory NSCLC 50 XL# XL# 50 refractory peripheral T 50 fallopian tube carcinoma 50 monotherapy 50 PRTX 50 cell lymphoma DLBCL 50 Cell Non Hodgkin 50 medically inoperable 50 HGS ETR1 50 TG# [003] 50 Atypical Hemolytic Uremic Syndrome 50 sorafenib Nexavar ® 50 SIR Spheres 50 Voraxaze ™ 50 metastatic pancreatic cancer 50 Actemra tocilizumab 50 GRN# 50 thymoma 50 CA4P 50 anti angiogenic agents 50 pouchitis 50 secondary hyperparathyroidism 50 acute myeloid leukemia AML 50 eculizumab 50 vinflunine 50 vWD 50 EGFR targeting 50 plus gemcitabine 50 dyslipidemia 50 Aurora kinase 50 tuberous sclerosis complex 50 immunomodulatory therapy 50 hepatitis C genotype 50 hereditary angioedema 50 Squamous 50 opioid induced bowel dysfunction 50 achieve sustained virologic 50 ThermoDox 50 carcinoid 50 velafermin 50 oncolytic vaccine 50 Rituximab 50 HspE7 50 tafamidis 50 Glioblastoma Multiforme GBM 50 azacitidine 50 Major Depressive Disorder 50 Genasense 50 Merkel cell carcinoma 50 Phase III Trial 50 Solesta